Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Mar;12(5):613-618.
doi: 10.1111/1759-7714.13824. Epub 2021 Jan 15.

Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody

Naoki Furuya  1 , Makoto Nishino  2   3 , Kazushige Wakuda  4 , Satoshi Ikeda  5 , Takashi Sato  3 , Ryota Ushio  6 , Shigeru Tanzawa  7 , Masafumi Sata  8 , Kentaro Ito  9
Affiliations
Multicenter Study

Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody

Naoki Furuya et al. Thorac Cancer. 2021 Mar.

Abstract

Background: Atezolizumab is a programmed death-ligand 1 (PD-L1) targeted monoclonal antibody that inhibits PD-L1 interacting with its receptors PD-1 and B7-1, thereby enhancing anticancer immunity. Some real-world efficacy and safety studies of anti-PD-1 antibody have been previously reported. However, there have been no reports investigating the efficacy of atezolizumab monotherapy in clinical practice which have focused on performance status and previous anti-PD-1 antibody treatment.

Methods: We retrospectively reviewed consecutive advanced NSCLC patients who received atezolizumab monotherapy between April 2018 and February 2019 at eight institutions. A total of 152 patients with NSCLC were enrolled in this study.

Results: A total of 38 patients (25%) had already been treated with anti-PD-1 treatment (nivolumab or pembrolizumab) before atezolizumab. The median OS and TTF was 384 days (12.8 months) (95% confidence interval [CI]: 206-424), and 42 days (1.4 months) (95% CI: 27-56) in all patients, respectively. ECOG PS 0 had significantly longer OS (median OS; not reached, p < 0.0001) and TTF (median TTF; 63 days, p = 0.012) compared with PS 1 or 2-3. Most retreated patients were unable to continue atezolizumab for a longer period, but seven patients (18.4%) were able to continue atezolizumab over four months as an ICI retreatment.

Conclusions: In previously treated advanced NSCLC patients, atezolizumab monotherapy demonstrated good efficacy and safety regardless of heavily treated patients in real-world clinical practice, and ECOG PS 0 was a favorable predictive factor. The efficacy of retreatment with atezolizumab was limited but was well tolerated in patients treated with prior anti-PD-1 antibody.

Keywords: anti-PD-L1; atezolizumab; non-small cell lung cancer; retreatment.

PubMed Disclaimer

Conflict of interest statement

N. Furuya has received speaker fees as honoraria from AstraZeneca, Chugai, Boehringer Ingelheim Japan, Eli Lilly Japan, Bristol Myers Squibb, Novartis, Taiho, Kyowa Kirin, MSD, and Pfizer.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier survival curves of OS and TTF (a, b) in all patients, and according to PD‐L1 status (c, d)
FIGURE 2
FIGURE 2
Kaplan–Meier survival curves of OS (a) and TTF (b) according to ECOG PS
FIGURE 3
FIGURE 3
Swimmers plot of atezolizumab according to the efficacy of prior anti‐PD‐1 treatment (N = 38)
See this image and copyright information in PMC

References

    1. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti‐PD‐L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. - PMC - PubMed
    1. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non‐small‐cell lung cancer (OAK): A phase 3, open‐label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. - PMC - PubMed
    1. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD‐L1‐expressing, locally advanced or metastatic non‐small‐cell lung cancer (KEYNOTE‐042): A randomised, open‐label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. - PubMed
    1. Gandhi L, Rodríguez‐Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. N Engl J Med. 2018;378(22):2078–92. - PubMed
    1. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first‐line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301. - PubMed

Publication types

MeSH terms

Substances